Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1.

Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1

Amazon

Johnson & Johnson

Pfizer

The VIX is showing that investors are feeling increasingly optimistic. This follows the S&P 500's 20% gain from its bear market low.

This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?

Merck and Co and partner Ridgeback Biotherapeutics said on Tuesday they had withdrawn their COVID-19 pill application in the European Union, months after the region's regulator did not back the drug citing insufficient data.

Merck, Ridgeback withdraw COVID drug application in EU

Floor & Decor Holdings

Generac Holdings

MongoDB

Dow Jones drug giant Merck is approaching its latest buy point. Stocks to buy and watch include Floor & Decor and Generac.

Dow Jones Drug Giant Merck Eyes Buy Point; 3 Other Leaders To Buy Or Watch

An early magazine advertisement for Merck's breakthrough asthma and allergy medicine, Singulair, featured a happy child, hanging upside-down from a tree. Asthmatic kids could now breathe easier, the text assured, and side effects were “usually mild” and “similar to a sugar pill.

Merck accused of downplaying early evidence of drug's brain impact

Apple

Amgen

Boeing

Salesforce

Goldman Sachs

Microsoft

Walgreens

The Dow Jones Industrial Average closed down 0.01%, or 4 points, spending most of the day in the red as investors digested the latest moves by central banks around the world.

Dow Jones Today: Index Flat as Investors Mull Global Rate Decisions

ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD outside the USA and Canada, to continue their collaboration in the peptide therapeutics area.

IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA

Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.

Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal

Merck & Co said on Tuesday its blockbuster immunotherapy Keytruda failed to meet one of the two main goals in a late-stage study testing it as a treatment option for a type of advanced gastric cancer.

Merck's Keytruda fails to meet one main goal in gastric cancer trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck has been on a five year bull run, thanks to its superstar immuno-oncology medicine Keytruda. With this drug on track to lose market exclusivity in 2028, the company has been slowly building an innovation engine capable of delivering growth in the next decade.

Is Merck Stock a Top Buy Right Now?

NVIDIA

The AI industry is still in its infancy, but Nvidia is already perfectly positioned to power its growth. Pharmaceutical outfit Merck is usually developing (or acquiring) more drug candidates than the market gives it credit for.

Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement

Keytruda sales totaled $5,795 million in Q1 2023, up 17% year-on-year, thanks partly to an increase in its indications for use. At the same time, Robert Davis does not actively use the share buyback program, and in the first quarter of 2023, Merck repurchased its shares for about $149 million. At the end of the first quarter of 2023, Merck's total debt was about $30.75 billion, a decrease of $3.88 billion from 2021.

Merck: Approaching The Accumulation Phase With An Expanding Product Portfolio

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Completes Acquisition of Prometheus Biosciences, Inc.

Merck Completes Acquisition of Prometheus Biosciences, Inc.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Trastuzumab & Chemo Met Primary Endpoint of PFS as First-Line Treatment for HER2-Positive Advanced Gastric or GEJ Adenocarcinoma.

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck stock (NYSE: MRK) currently trades at $110 per share, roughly 43% above its level in March 2021, and it looks fully valued. Merck saw its stock trading.

How Has Merck Stock Performed During The 2022-23 Inflation Shock?

Drugmaker Merck & Co. MRK, +0.12% on Tuesday said that a U.S. district court had validated U.S. patent protection for its neuromuscular drug Bridion through “at least January 2026.” The announcement followed what the company said was a favorable ruling from the U.S. District Court for the District of New Jersey over a patent-infringement lawsuit related to the drug, which according to the FDA is administered to reverse the effects of other drugs used to paralyze a patient's vocal cords and allow breathing-tube insertion for surgery.

Merck says court ruled in its favor over patent-infringement suit

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION.

U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?

Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 7:00 PM ET Company Participants Caroline Litchfield - Chief Financial Officer Conference Call Participants Frank Clyburn - Goldman Sachs Dean Li - Executive Vice President and President Frank Clyburn Okay, let's get underway. Welcome everybody to the afternoon session here at the Goldman Sachs 44th Annual Healthcare Conference.

Merck & Co., Inc. (MRK) Goldman Sachs 44th Annual Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist at EASL 2023.

Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023

AbbVie

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outperforming the S&P 500 by 1.40%. Year-to-date the portfolio is up 6.66% and trailing the S&P 500 by 2.99%. Since inception, the portfolio is generating alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Passively Outpacing The Market

FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.

Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer.

FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

Duke Energy

Walmart

While Wall Street appears pleased with the latest hotter-than-expected jobs report, investors might benefit from the best defensive stocks to buy. At first, such a notion seems overly pessimistic given the robust labor market readout.

News for Merck Stock (MRK)